RS62932B1 - Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a - Google Patents

Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a

Info

Publication number
RS62932B1
RS62932B1 RS20220142A RSP20220142A RS62932B1 RS 62932 B1 RS62932 B1 RS 62932B1 RS 20220142 A RS20220142 A RS 20220142A RS P20220142 A RSP20220142 A RS P20220142A RS 62932 B1 RS62932 B1 RS 62932B1
Authority
RS
Serbia
Prior art keywords
preparation
fluticasone propionate
ophthalmic aqueous
sterile ophthalmic
propionate form
Prior art date
Application number
RS20220142A
Other languages
English (en)
Inventor
Jean-Michel Bukowski
Akshay Nadkarni
José L Boyer
Brigitte Duquesroix-Chakroun
Tomas Navratil
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of RS62932B1 publication Critical patent/RS62932B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
RS20220142A 2019-07-23 2020-07-21 Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a RS62932B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02
EP20186965.8A EP3769753B1 (en) 2019-07-23 2020-07-21 Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Publications (1)

Publication Number Publication Date
RS62932B1 true RS62932B1 (sr) 2022-03-31

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220142A RS62932B1 (sr) 2019-07-23 2020-07-21 Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a

Country Status (21)

Country Link
US (3) US11406596B2 (sr)
EP (1) EP3769753B1 (sr)
JP (2) JP7021301B2 (sr)
KR (1) KR20220038443A (sr)
CN (2) CN115120557B (sr)
AU (1) AU2020317084A1 (sr)
CA (1) CA3145055A1 (sr)
CY (1) CY1124930T1 (sr)
DK (1) DK3769753T3 (sr)
ES (1) ES2905793T3 (sr)
HR (1) HRP20220165T1 (sr)
HU (1) HUE057416T2 (sr)
LT (1) LT3769753T (sr)
MD (1) MD3769753T2 (sr)
MX (1) MX2022000928A (sr)
PL (1) PL3769753T3 (sr)
PT (1) PT3769753T (sr)
RS (1) RS62932B1 (sr)
SI (1) SI3769753T1 (sr)
TW (1) TW202116326A (sr)
WO (1) WO2021014348A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
CA2764473A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
BR112014027681B8 (pt) * 2012-05-08 2023-10-31 Aciex Therapeutics Inc Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
CN104869980A (zh) * 2012-12-17 2015-08-26 葛兰素集团有限公司 用于治疗炎症性病症和/或变应性病症的左卡巴斯汀和糠酸氟替卡松的组合
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑

Also Published As

Publication number Publication date
JP7494230B2 (ja) 2024-06-03
DK3769753T3 (da) 2022-01-31
HUE057416T2 (hu) 2022-05-28
LT3769753T (lt) 2022-05-10
TW202116326A (zh) 2021-05-01
WO2021014348A1 (en) 2021-01-28
JP2022062172A (ja) 2022-04-19
US20210023001A1 (en) 2021-01-28
MD3769753T2 (ro) 2022-04-30
CN111821261B (zh) 2022-07-26
EP3769753B1 (en) 2021-11-17
ES2905793T3 (es) 2022-04-12
JP7021301B2 (ja) 2022-02-16
MX2022000928A (es) 2022-02-22
HRP20220165T1 (hr) 2022-04-29
CY1124930T1 (el) 2023-01-05
PL3769753T3 (pl) 2022-04-04
SI3769753T1 (sl) 2022-04-29
KR20220038443A (ko) 2022-03-28
CA3145055A1 (en) 2021-01-28
PT3769753T (pt) 2022-02-15
JP2021017449A (ja) 2021-02-15
EP3769753A1 (en) 2021-01-27
CN111821261A (zh) 2020-10-27
CN115120557A (zh) 2022-09-30
US20220323352A1 (en) 2022-10-13
AU2020317084A1 (en) 2022-03-03
US11406596B2 (en) 2022-08-09
CN115120557B (zh) 2024-05-07
US20220241296A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
HUE065246T2 (hu) Sebészeti rendszer szem belnyomás pontos csökkentéséhez
SI3769753T1 (sl) Postopek za pripravo sterilnih oftalmičnih vodnih nanokristalnih suspenzij flutikazon propionata oblike A
EP3518727A4 (en) METHOD AND APPARATUS FOR HANDLING SIDE WALL OF BODY LIGHT OR BODY CAVITY
SG11202108238VA (en) Process for the preparation of methionine
GB2582265B (en) A method for adjusting the suspension of a vehicle
EP3880269A4 (en) FILTERS FOR SURGICAL PROCEDURES
IL287423A (en) Antibodies and methods for treating influenza E infection
SG11202108756TA (en) Compound for the sequestration of undesirable antibodies in a patient
IT201900004041A1 (it) Procedimento per la preparazione di un derivato del fulvestrant
EP3743834A4 (en) PROCESS FOR OPTIMIZING THE CONSTRUCTION OF A CAR BODY
EP3853659A4 (en) STRUCTURES AND METHODS OF CRACK FORMING FOR REFRACTIVE CORRECTION
EP3870637A4 (en) NANOCELLULOSE HYDROPHOBIC MODIFICATION PROCESS DURING MANUFACTURING
EP3845265A4 (en) MEDICAL BALLOON PRODUCTION METHOD
EP3847138A4 (en) METHOD FOR SEPARATION OF A HOLLOW GLASS BODY FROM A GLASS TUBE AND METHOD AND SYSTEM FOR MANUFACTURING A RECEPTACLE
IL289904A (en) A process for preparing biphenylamines
EP3572221A4 (en) MANUFACTURING METHOD FOR A FOLDED FILM AND MANUFACTURING METHOD FOR A FOLDED PACKAGING BODY
HUP1900315A1 (hu) Ipari eljárás nagytisztaságú ösztetrol hatóanyag elõállítására
MA53146A (fr) Procédé de préparation de suspensions nanocristallines de propionate de fluticasone aqueux ophtalmique stérile
EP4076468A4 (en) FILTER AID FOR NON-AQUEOUS LIQUIDS
IL286054A (en) A process for the preparation of a modified imidazoquinoline
IL281333A (en) A method to reduce the risk in a clinical trial
HUE055078T2 (hu) Eljárás cellulóz-karbamát elõállítására
FI4021505T3 (fi) Lääke tartuntatautien hoitamiseksi
EP4072578A4 (en) BIOMOLECULES FOR THE TREATMENT OF CORNEA PATHOLOGIES
KR102220126B9 (ko) 플랜지의 프리폼 제조방법